查詢結果分析
相關文獻
- Sorafenib抗癌藥與臨床應用
- Large Renal Cell Carcinoma with Multiple Metastases Presenting as Low Back Pain
- 晚期腎細胞癌之標靶治療
- 晚期腎細胞癌之用藥探討
- Renal Cell Carcinoma Presented as a Traumatic Ruptured Kidney
- 肝癌的成因及危險因子
- Tumor Angiogenesis and Metastasis: Correlation in Invasive Renal Cell Carcinoma
- 肝癌病患家屬參加教育心理團體成效探討
- N-Acetyltransferase in Healthy Human Liver and Hepatoma Tissues
- Use of Color Ultrasound in Percutaneous Intravascular Ethanol Injection into the Supplying Vessel of a Hepatocellular Carcinoma: Report of a Case
頁籤選單縮合
題名 | Sorafenib抗癌藥與臨床應用=Clinical Approach to Sorafenib in Cancer Treatment |
---|---|
作者姓名(中文) | 劉素靜; 黃佳真; 蔡斌智; 林梅芳; | 書刊名 | 藥學雜誌 |
卷期 | 28:4=113 2012.12[民101.12] |
頁次 | 頁88-90 |
分類號 | 418.31 |
關鍵詞 | 酪胺酸激酶抑制劑; 腎細胞癌; 肝癌; 甲狀腺細胞癌; Sorafenib; |
語文 | 中文(Chinese) |
中文摘要 | Sorafenib近來核准的適應症為治療晚期腎細胞癌與肝癌。 Sorafenib為一新酪胺酸激酶抑制劑可抑制腫瘤生長與血管新生,對於病人而言是口服耐受性佳有效及安全的藥品,未來希望在治療反應率或合併其他的治療上有更多研究,以提高病人的存活率。 |
英文摘要 | Sorafenib is currently approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. In clinical study, Sorafenib, a novel inhibitor of tyrosine kinases receptor in molecular targeted remedy, can prevent tumor growth, proliferation and angiogenesis. It is orally well-tolerated and safe for patients with advanced solid tumor. Hopefully, further studies will be performed to evaluate remedy rate and effectiveness of sorafenib in combination with other therapies to improve the survival rate for patients. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。